Survey: Wielding AI magic in clinical trials requires a master’s touch

[Adobe Stock]

eClinical’s Industry Outlook 2024 report highlights a significant acceleration in AI/ML adoption for clinical trials. Over half of professionals (53%) in functions like clinical operations, data management, and biometrics now see these technologies as central to streamlining trials by 2024, surpassing the emphasis on automation that dominated last year. Despite this hype cycle, a core lesson emerges: progress will be uneven as we learn to harness this new form of “magic.”

The sorcerer’s apprentice: Enthusiasm and the need for mastery

Much like the eager apprentice in Disney’s animated film “Fantasia,” which itself is inspired by Goethe’s “Der Zauberlehrling”(“Sorcerer’s Apprentice“), many in the clinical research field seem eager to unleash the power of AI even before fully grasping the strategic investment required for mastery…

Read more
  • February 16, 2024
  • 0

BIOiSIM assigns ‘credit scores’ to drug candidates 

VeriSIM Life, a San Francisco-based startup, has created BIOiSIM, an AI-powered platform that simulates drug compound behavior in the human body by acting like a virtual laboratory. It assigns each a predictive “credit score” predicting its viability for drug development.

“It’s like a FICO score for drug development,” founder and CEO Dr. Jo Varshney said. BIOiSIM’s scoring system draws from an inferential search space of more than 1 billion drug-like compounds and capacity to model 800 billion total simulation scenarios powered by 10 billion deep learning neural network effects. The vast search space of drug-like compounds and data processing capabilities enable it to evaluate numerous factors such as its potency, selectivity, and safety profile to determine a drug’s overall likelihood of success.

BIOiSIM focuses on predictive insights

The considerable scale of data allows for a comprehensive analysis of drug compounds, bolstering the pr…

Read more
  • February 8, 2024
  • 0